Compare Charles River Laboratories Intl. Inc (CRL) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs ING Groep NV — how do they compare? Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B), while ING Groep NV trades at $35.34 (market cap $101.22B). The key difference: ING Groep NV is far larger — about 7.5× Charles River Laboratories Intl. Inc's market cap, and ING Groep NV pays a 3.73% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | ING | |
|---|---|---|
Market Cap | $13.46B | $101.22B |
Sector | Health | Financials |
52-Week High | $282.00 | $35.92 |
52-Week Low | $145.57 | $23.66 |
Enterprise Value | $16.30B | — |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
ING trades at $35.66, up 1.19% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 forecast. Revenue growth is steady, reaching $22.90B in 2025, and the company recently raised its 2026-2027 outlook, driven by robust net interest income and lending growth. A dividend of $0.46 per share is scheduled for payment on August 17, 2026.
The outlook for ING is positive, supported by upward earnings revisions, a favorable valuation with a P/E of 13.24, and institutional bullishness. Key risks include persistent negative operating cash flows and sensitivity to interest rate changes. The stock's momentum and fundamental strength present a compelling case for growth-oriented investors, though cash flow trends warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
